Function-First In Vivo CAR Development with Fully Human Single-Domain VH Antibodies
- Address the development gap between functional CAR construct design (binding specificity, signaling domains, avidity) and targeted in vivo delivery to specific immune lineages
- Leverage NonaCarFx™, a functional, library-scale fully human VH-CAR screening platform, to identify binders that elicit CAR activity early and pair with Nona’s LNP conjugation platform for active targeting
- Develop binders against key T cell targets (CD2, CD3, CD5, CD7, CD8a) and apply high-resolution screening of TCR mimic, pH-dependent, hypoxic, and isoform-specific binders to reduce on-target, off-tumor toxicity